More Videos
SPECIAL REPORT
MOST SHARED
- Seeking Innovation in Health Care
- Today's Market Action
- Driving Health Care Innovation
- Herbalife Vs. Hedge Funds
- Israel: Leader of Business Innovation
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Warren Buffett and Bill Gates: Keeping America Great
- Low Interest Rate Investing
- Week Ahead: Investors Go for Quality, Assess Recovery
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
- Fed Reform? Not So Fast.
- Oil Next Week: What Traders Will Be Watching
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- Cities With the Most Home Price Reductions
- White House Plans to Freeze Spending to Cut Deficit
- This Year's Biggest Thanksgiving Leftover: Cash
- Oil Next Week: What Traders Will Be Watching
RSS FEED
Pharma's Market
Text Size 
This morning Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the highly anticipated test results on their once-a-week, Type 2 diabetes drug. One analyst recently called this the most important biotech data of the second half of this year. Many expect the drug to become a multi-billion dollar blockbuster.
AMLN and LLY are partners on the twice-a-day injectable diabetes drug Byetta. Over the past few weeks they started doing direct-to-consumer advertising for the first time. And in the last week I've noticed that the campaign has escalated from a very basic brand-awareness tone to a more pointed approach where they're even mentioning how much weight patients lost in clinical trials.
I'm assuming the FDA is cool with that, but it does make me wonder. Analysts have long talked about how they believe a lot of people who are not diabetic are going on Byetta just to help them shed pounds. That would be what's called "off-label use" and Amylin and Lilly are prohibited from promoting it as a diet drug. Anyway, I digress.
So, the companies say that the once-a-week Byetta resulted in a greater reduction in blood-sugar levels than was achieved in a mid-stage test and with twice-a-day Byetta. Three out of four patients got their blood-sugar level below the recommended benchmark. There was a 30% lower incidence of mild, transient nausea which is a common side-effect with twice-a-day Byetta.
However, on average patients lost about eight pounds. And because that's comparable to the weight loss seen with twice-a-day, investors seem to be disappointed and are selling shares of AMLN and ALKS as I write this, while LLY has been up and down. Alkermes makes the technology that allows the drug to last a week in the body and would receive a royalty on sales. LLY and AMLN would split the rest evenly.
 |
CNBC.com Byetta Needle |
Amylin execs were quick to point out that 90% of the 300 or so patients in the clinical trial finished the study. The once-a-week Byetta comes with a 23 gauge needle and Amylin officials say, "It was very well accepted."
 |
CNBC.com 23 Gauge Needle |
The companies are saving them for publication in a peer-reviewed medical journal which in the scientific and investor communities give drug data additional credibility. Today, though, investors don't seem to be assigning any.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes